Orexin receptor agonists are currently under development for the treatment of disorders of hypersomnolence. Early clinical trial results are exciting for both patients and clinicians, as they represent the potential to change the treatment landscape.
When: July 29, 2026
|
Sleep apnoea and sleep-disordered breathing are increasingly recognised as multifactorial conditions, with orofacial myofunctional health playing a critical yet often under-addressed role.
When: August 19, 2026
|
This webinar will present new findings from the Quality Use of Medicines for Insomnia and Sleep Health (QUMISH) program, a recently completed Commonwealth-funded grant conducted by the Australasian Sleep Association in association with the Pharmaceutical Society of Australia.
When: September 16, 2026
|
Sleep disruption is often framed as an inevitable part of raising a family, yet parental sleep health remains under-recognised and under-addressed in both research and clinical care. While evidence-based interventions can meaningfully support parents, they are rarely embedded in routine services, leaving many families feeling disempowered, confused, or uninformed.
When: September 30, 2026
|
Sleep DownUnder 2026 has had to move dates and venue due to a clash with ESRS. We're heading back to sunny Brisbane on 11-14 November for the largest sleep gathering in our region.
When: November 11–14, 2026
Where: South Brisbane, QLD
|